Sanofi signs manufacturing contract with Isarna Therapeutics
To manufacture clinical and commercial grade antisense oligonucleotides
Sanofi has agreed to manufacture clinical and commercial grade antisense oligonu-cleotide (ASO) for Isarna Therapeutics (formerly Antisense Phama) of Germany.
Isarna says the agreement will enable the company to advance its next-generation ASOs rapidly into clinical trials.
Financial details of the agreement have not been disclosed.
‘At Isarna, we are convinced that the best possible manufacturing is critical as we seek to maintain an accelerated timeline for product development,’ said Philippe Calais, CEO of Isarna Therapeutics.
Sanofi’s Industrial Affairs division will act as Isarna Therapeutics’ contract manufacturer. Sanofi will scale-up and validate the production of ASOs and supply future commercial batches.
Manufacturing will take place at Sanofi’s plant in Frankfurt.
